Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FRISCO, Texas, Jan. 26, 2016 -- Greatbatch Inc., (NYSE:GB) today announced that a jury in the United States District Court for the District of Delaware returned a verdict finding that AVX Corporation and AVX Filters Corporation infringed two Greatbatch patents, and in the process awarded Greatbatch $37.5 million in damages. The complaint, filed in April 2013, alleged that AVX had infringed Greatbatch patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate its patented technology.
The jury's decision marked an important milestone in Greatbatch’s effort to defend its patented technology. “Greatbatch is committed to challenging willful and deliberate patent infringement and to taking all steps necessary to ensure that our intellectual property is protected,” said Thomas J. Hook, Greatbatch president & CEO. "I want to express my sincere appreciation for the time and careful attention the Court and the jury gave this important case."
During trial, Greatbatch presented evidence that certain AVX products infringed claims of U.S. Patent Nos. 5,905,627 and 5,333,095. In advance of trial, the Court determined that the jury should also include damages for infringement of U.S. Patent No. 6,888,715.
In awarding Greatbatch $37.5 million in damages, the jury also confirmed the validity of Greatbatch’s asserted patents, as well as two other Greatbatch patents that AVX had challenged.
Additional information about the case – Greatbatch Ltd. v. AVX Corporation and AVX Filters Corporation, Civil Action No. 13-cv-723-LPS – can be obtained from publicly available court records. Greatbatch was represented in this case by Harris Beach PLLC.
About Greatbatch, Inc.
Greatbatch, Inc. (NYSE:GB) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopaedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company’s brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available at www.greatbatch.com.
In October 2015, Greatbatch, Inc. completed its acquisition of Lake Region Medical, with the combined company expected to be renamed Integer Holdings Corporation later this year (subject to shareholder approval).
Investor Relations Contact: Anthony Borowicz [email protected] tel 716-759-5809 Media Contact: Christopher Knospe [email protected] tel 716-759-5727
